Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives $3.33 Average Price Target from Brokerages

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) have earned a consensus rating of “Moderate Buy” from the eight research firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $3.3333.

RVPH has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating and set a $4.00 target price on shares of Reviva Pharmaceuticals in a research note on Tuesday, December 23rd. Wall Street Zen raised Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 27th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research report on Wednesday, October 8th. D. Boral Capital reissued a “buy” rating and issued a $2.00 target price on shares of Reviva Pharmaceuticals in a research report on Tuesday, December 23rd. Finally, Chardan Capital restated a “buy” rating and set a $2.00 price target on shares of Reviva Pharmaceuticals in a research note on Monday, January 5th.

Reviva Pharmaceuticals Stock Down 3.1%

Shares of NASDAQ RVPH opened at $0.33 on Wednesday. The firm’s 50-day moving average price is $0.46 and its 200-day moving average price is $0.47. Reviva Pharmaceuticals has a 52-week low of $0.25 and a 52-week high of $2.15. The company has a market cap of $37.51 million, a PE ratio of -0.71 and a beta of 0.08.

Reviva Pharmaceuticals (NASDAQ:RVPH) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.05. As a group, equities research analysts anticipate that Reviva Pharmaceuticals will post -0.97 EPS for the current fiscal year.

Institutional Trading of Reviva Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Armistice Capital LLC bought a new position in Reviva Pharmaceuticals in the second quarter worth approximately $1,026,000. 683 Capital Management LLC bought a new stake in shares of Reviva Pharmaceuticals during the 2nd quarter valued at $381,000. Persistent Asset Partners Ltd increased its stake in shares of Reviva Pharmaceuticals by 300.0% in the 2nd quarter. Persistent Asset Partners Ltd now owns 641,174 shares of the company’s stock worth $244,000 after purchasing an additional 480,864 shares in the last quarter. Millennium Management LLC raised its holdings in Reviva Pharmaceuticals by 15.0% in the 3rd quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock worth $631,000 after purchasing an additional 223,178 shares during the period. Finally, Lido Advisors LLC purchased a new position in Reviva Pharmaceuticals during the third quarter valued at $37,000. 63.18% of the stock is owned by hedge funds and other institutional investors.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.